These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30182909)

  • 21. T-cell therapy for chronic viral hepatitis.
    Bertoletti A; Tan AT; Koh S
    Cytotherapy; 2017 Nov; 19(11):1317-1324. PubMed ID: 28847469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure.
    Asselah T; Loureiro D; Boyer N; Mansouri A
    Lancet Gastroenterol Hepatol; 2019 Nov; 4(11):883-892. PubMed ID: 31609242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eradication Strategies for Chronic Hepatitis B Infection.
    Wilson EM; Tang L; Kottilil S
    Clin Infect Dis; 2016 Jun; 62 Suppl 4(Suppl 4):S318-25. PubMed ID: 27190322
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.
    Wooddell CI; Yuen MF; Chan HL; Gish RG; Locarnini SA; Chavez D; Ferrari C; Given BD; Hamilton J; Kanner SB; Lai CL; Lau JYN; Schluep T; Xu Z; Lanford RE; Lewis DL
    Sci Transl Med; 2017 Sep; 9(409):. PubMed ID: 28954926
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does antiviral therapy for chronic hepatitis B reduce the risk of hepatocellular carcinoma?
    Abu-Amara M; Feld JJ
    Semin Liver Dis; 2013 May; 33(2):157-66. PubMed ID: 23749672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis B cure: From discovery to regulatory approval.
    Lok AS; Zoulim F; Dusheiko G; Ghany MG
    J Hepatol; 2017 Oct; 67(4):847-861. PubMed ID: 28778687
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B.
    Nassal M
    Gut; 2015 Dec; 64(12):1972-84. PubMed ID: 26048673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Control of viral transcripts as a concept for future HBV therapies.
    Seeger C
    Curr Opin Virol; 2018 Jun; 30():18-23. PubMed ID: 29453098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis B core protein as a therapeutic target.
    Mak LY; Wong DK; Seto WK; Lai CL; Yuen MF
    Expert Opin Ther Targets; 2017 Dec; 21(12):1153-1159. PubMed ID: 29065733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging drugs for the treatment of hepatitis B.
    Fung J; Lai CL; Seto WK; Yuen MF
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):183-93. PubMed ID: 26940510
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toward a Cure for Hepatitis B Virus Infection: Combination Therapy Involving Viral Suppression and Immune Modulation and Long-term Outcome.
    Wu D; Ning Q
    J Infect Dis; 2017 Nov; 216(suppl_8):S771-S777. PubMed ID: 29156046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Potential use of serum HBV RNA in antiviral therapy for chronic hepatitis B in the era of nucleos(t)ide analogs.
    Lu F; Wang J; Chen X; Xu D; Xia N
    Front Med; 2017 Dec; 11(4):502-508. PubMed ID: 29170915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical relevance of the study of hepatitis B virus covalently closed circular DNA.
    Kumar R; Pérez-Del-Pulgar S; Testoni B; Lebossé F; Zoulim F
    Liver Int; 2016 Jan; 36 Suppl 1():72-7. PubMed ID: 26725901
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B.
    Lai CL; Wong D; Ip P; Kopaniszen M; Seto WK; Fung J; Huang FY; Lee B; Cullaro G; Chong CK; Wu R; Cheng C; Yuen J; Ngai V; Yuen MF
    J Hepatol; 2017 Feb; 66(2):275-281. PubMed ID: 27639844
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus.
    Tsuge M; Uchida T; Hiraga N; Kan H; Makokha GN; Abe-Chayama H; Miki D; Imamura M; Ochi H; Hayes CN; Shimozono R; Iwamura T; Narumi H; Suzuki T; Kainoh M; Taniguchi T; Chayama K
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Role for the Host DNA Damage Response in Hepatitis B Virus cccDNA Formation-and Beyond?
    Schreiner S; Nassal M
    Viruses; 2017 May; 9(5):. PubMed ID: 28531167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients.
    Laras A; Koskinas J; Dimou E; Kostamena A; Hadziyannis SJ
    Hepatology; 2006 Sep; 44(3):694-702. PubMed ID: 16941694
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Present and Future Therapies for Chronic Hepatitis B.
    Tao Y; Wu D; Zhou L; Chen E; Liu C; Tang X; Jiang W; Han N; Li H; Tang H
    Adv Exp Med Biol; 2020; 1179():137-186. PubMed ID: 31741336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Control and Eradication Strategies of Hepatitis B Virus.
    Shih C; Chou SF; Yang CC; Huang JY; Choijilsuren G; Jhou RS
    Trends Microbiol; 2016 Sep; 24(9):739-749. PubMed ID: 27287929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging therapeutics and relevant targets for chronic Hepatitis B.
    Song IH
    Turk J Gastroenterol; 2016 May; 27(3):210-5. PubMed ID: 27210776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.